Question 1

What type of cell therapies is Caribou developing?

Accepted Answer

Caribou is developing allogeneic, or off-the-shelf, CAR-T cell therapies from healthy donor cells to address the limitations of currently approved therapies.

Question 2

What is Caribou's focus?

Accepted Answer

Caribou is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for devastating human diseases.

Question 3

How does Caribou use cookies on its website?

Accepted Answer

Caribou uses cookies to improve user experience and analyze site traffic, but does not collect user data for targeting or marketing purposes. Users can learn more about how Caribou uses cookies, including how to disable them, by viewing the company's privacy policy.

Question 4

What is Caribou's technology platform?

Accepted Answer

Caribou's patented CHRDNA (CRISPR Hybrid RNA-DNA) technology enables superior specificity and precision in complex genome editing, including multiplex gene knockout and insertion, while maintaining genomic integrity.

Question 5

How is Caribou enhancing the activity of its cell therapies?

Accepted Answer

Caribou uses its CHRDNA technologies to "armor" its cell therapies through multiple genome-editing strategies, including checkpoint disruption, immune cloaking, or a combination of these two strategies, to enhance activity against devastating diseases.

Caribou Biosciences

Company Overview

Company Name

Address

Website

Phone

Employees

About Caribou Biosciences

Similar Companies

Frequently Asked Questions about Caribou Biosciences

What type of cell therapies is Caribou developing?

What is Caribou's focus?

How does Caribou use cookies on its website?

What is Caribou's technology platform?

How is Caribou enhancing the activity of its cell therapies?

Technologies Used

Social Profiles

Key Decision Makers